Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt

Table 1 Basic clinical data

Clinical characteristic	TAF (n = 32)	TDF (n = 35)	ETV (n = 70)	Statistic	P value	Total (n = 137)
Gender, n (%)				X2 = 1.033	0.597
Male	20	18	37			75
Female	12	17	33			52
Age (yr, mean ± SD)	53.8 ± 8.5	54.4 ± 7.3	54.5 ± 10.3	t = 0.234	0.815	54.3 ± 9.2
Child-Pugh classification				X2 = 1.623	0.805
A	9	14	21			44
B	18	17	37			72
C	5	4	12			21
Child-Pugh score	6.94 ± 1.29	7.46 ± 2.14	7.26 + 1.64	F = 1.119	0.330	7.31 ± 1.75
MELD score	10.37 ± 2.94	9.69 ± 2.96	10.41 ± 2.93	F = 0.775	0.463	10.22 ± 2.93
Prothrombin time (s)	14.40 ± 1.86	15.14 ± 2.81	14.95 ± 2.73	F = 0.930	0.354	14.74 ± 2.59
Albumin (g/L)	35.27 ± 5.65	34.14 ± 5.01	34.43 ± 4.33	F = 0.496	0.610	34.55 + 4.82
eGFR (mL/min/1.73 m2)	91.22 ± 10.67	90.37 ± 14.24	90.19 ± 12.05	F = 0.078	0.925	90.47 ± 12.27
Cr (μmol/L)	75.04 ± 36.60	78.07 ± 39.72	71.56 ± 23.70	F = 0.940	0.349	74.04 ± 31.51
Total bilirubin (μmol/L)	36.83 ± 14.74	38.62 ± 17.21	34.10 ± 15.69	F = 0.868	0.387	35.89 ± 15.89
PPG before TIPS (mmHg)	25.41 ± 4.82	25.71 ± 5.49	25.84 ± 5.49	F = 0.073	0.929	25.71 ± 5.31
PPG after TIPS (mmHg)	9.52 ± 2.28	9.97 ± 3.04	10.13 ± 2.81	F = 0.530	0.590	9.95 ± 2.75
Deaths in 24 mo, n (%)	3 (9.4)	4 (11.4)	10 (14.3)	X2 = 0.517	0.772	17 (13.7)
HCC in 24 mo, n (%)	2 (6.3)	2 (5.7)	7 (10)	X2 = 0.712	0.700	11 (9.3)
HE in 24 mo, n (%)	6 (18.8)	8 (22.9)	18 (25.7)	X2 = 0.770	0.681	32 (25.4)

MELD: Model for end-stage liver disease; TIPS: Transjugular intrahepatic portosystemic shunt; PPG: Portal pressure gradient; HE: Hepatic encephalopathy; HCC: Hepatocellular carcinoma; eGFR: Estimated glomerular filtration rate; TAF: Tenofovir alafenamide fumarate; TDF: Tenofovir disoproxil fumarate; ETV: Entecavir.